NCT03450915 - A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine | Biotech Hunter

Enrollment

12,460

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

July 2, 2020

Study Completion Date

October 23, 2020

Conditions

Influenza

Interventions

BIOLOGICAL

M-001

A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.

BIOLOGICAL

Saline

0.9% sodium chloride (NaCl)

Trial Locations (2)

Jagiellońskie Centrum Innowacji Sp.z o.o., Krakow

Jagiellońskie Centrum Innowacji Sp.z o.o., Krakow